 |
 |
 |
Welcome to IMUGENE
Imugene Limited is an Australian based pharmaceutical company with a drug delivery platform at the centre of its assets. It uses its proprietary drug delivery technology to improve the efficacy and safety of a diverse number of existing prescription and over the counter medicines. Its platform technology, known as Linguet™, enables the active ingredient of drugs to be absorbed straight into the bloodstream when placed inside the cheek (via the buccal mucosa) or under the tongue (sublingual).
How does Linguet differ from other buccal or sublingual delivery platforms?
There are two key differentiators for the Linguet intellectual property and proprietary know-how. The first is that Linguet is manufactured using traditional dry tableting processes making it feasible and cost efficient to manufacture. The second is that Linguet allows for drug formulation where slight modifications to the ratio of PEG's* produce Linguet's having different dissolution rates allowing flexibility of mucosal penetration when incorporating different active pharmaceutical drugs. Linguet™ drug delivery technology helps protect small molecule drugs in oral delivery, including enhanced absorption across the oral membranes or by swallowing:
* PEG's are short for polyethylene glycol's with different lengths. PEG's are known to enhance the transport of drugs across mucosal membranes. ** Strachan I and Greener M Pharmacy in Practice 2005;15: 411–414  Dysphagia is the medical term for the symptom of difficulty in swallowing.
According to the Canadian Association of Speech-Language Pathologists and Audiologists, "We swallow on the average, about 600 times a day. It's estimated that about one in 10 people over 50 have some type of swallowing disorder". |
LATEST NEWS &
|
